Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Molecular Cancer Therapeutics|August 3, 2007
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in miceUrban Emmenegger, Yuval Shaked, Shan Man, et al.
Science Advances|April 16, 2025
In vivo and in situ monitoring of doxorubicin pharmacokinetics with an implantable bioresorbable optical sensorMartina Corsi, Elena Maurina, Salvatore Surdo, et al.
Journal of Clinical Medicine|October 29, 2025
Pharmacokinetics and Monitoring of Methotrexate in Adults with Acute Lymphoblastic Leukaemia: A 10-Year Follow-Up at an Italian CentrePasquale Fabio Calabrò, Letizia Biso, Marianna Lastella, et al.
Biochemical Pharmacology|April 7, 2019
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamicsTeresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
The British Journal of Ophthalmology|November 10, 2009
Periorbital necrotising fasciitisDavide Lazzeri, Stefano Lazzeri, Michele Figus, et al.
Cancer|August 12, 2014
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patientsLisa Derosa, Luca Galli, Paola Orlandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancerAntonello Di Paolo, Monica Lencioni, Federica Amatori, et al.
The Journal of Clinical Endocrinology and Metabolism|August 24, 2013
Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1Teresa Di Desidero, Anna Fioravanti, Paola Orlandi, et al.
American Journal of Cancer Research|August 15, 2022
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancerLorenzo Fornaro, Gianna Musettini, Paola Orlandi, et al.
Pharmacogenomics|December 15, 2015
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degenerationStefano Lazzeri, Paola Orlandi, Paolo Piaggi, et al.
Pageof 16